← ADMA BIOLOGICS, INC. (ADMA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
ADMA BIOLOGICS, INC. (ADMA)
Biological Products, (No Diagnostic Substances) · market cap $2.1B · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
ADMA Biologics (ADMA) is a commercial-stage biologics company focused on plasma-derived immunoglobulin therapies, with two Phase 3 assets targeting Primary Immune Deficiency Disorders (PIDD) — RI-002 and Nabi-IGIV 10% — and an earlier-stage RI-001 in Phase 2 for upper respiratory tract infection. The company has executed a sharp revenue inflection, growing from $81M in 2021 to $510M in 2025, and turned solidly profitable in 2024-2025, though it carries $62M net debt against $138M cash. At a $2.06B market cap, the stock trades at roughly 4x trailing revenue.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| RI-002 | Phase 3 | Primary Immune Deficiency Disorder |
| Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%] | Phase 3 | Primary Immune Deficiency Disorders (PIDD) |
| RI-001 | Phase 2 | Upper Respiratory Tract Infection |
Price & technical context
3-month
+9.8%
6-month
+9.5%
12-month
-33.2%
52-wk range
$7.60–$20.38
vs 50-day MA
+6.9%
vs 200-day MA
-14.4%
Realized vol
55.4%
Max drawdown
-69.0%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ADMA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.